In 2017, ‘‘CCHT’’ invested Shanghai Ruizhou Biotech Co., Ltd. (hereinafter referred to as ‘‘Shanghai Ruizhou’’, which is mainly targeted at the research & development of 20-valent pneumococcal polysaccharide conjugate vaccine project.

The 24-valent pneumococcal polysaccharide conjugate vaccine has the most advanced technology in the world. It is an alternative product of Pfizer’s 13-valent pneumococcal conjugate vaccine and its specificity is targeted at the Chinese population. Therefore, it has stronger protection, higher protection coverage, more advanced technology and huge market potential.

Dr. ZHU Xianchao, the technology leader, graduated from University of California in the United States. He has been engaged in the development of new-type vaccines for more than 10 years as a senior scientist. Later on, he worked in the Research & Development Center of Greater China of United States Pharmacopoeial Convention. He has rich experience in product development.